A second look at efficacy criteria for onychomycosis: Clinical and mycological cure

British Journal of Dermatology

Volumn 170, Issue 1, 2014, Pages 182-187

  Ghannoum, M ^a   Isham, N ^a   Catalano, V ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT;

ARTICLE; CLINICAL EFFECTIVENESS; DERMATOPHYTE; FOLLOW UP; FUNGUS CULTURE; FUNGUS HYPHAE; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TOENAIL ONYCHOMYCOSIS; TREATMENT DURATION; FEMALE; MALE; MULTICENTER STUDY (TOPIC); ONYCHOMYCOSIS; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ANTIFUNGAL AGENTS; FEMALE; HUMANS; MALE; MULTICENTER STUDIES AS TOPIC; ONYCHOMYCOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84892421863     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12594     Document Type: Article

References (39)

1. Roberts DT,. Prevalence of dermatophyte onychomycosis in the United Kingdom: results of an omnibus survey. Br J Dermatol 1992; 126: 23-7.
2. Elewski BE, Charif MA,. Prevalence of onychomycosis in patients attending a dermatology clinic in northeastern Ohio for other conditions. Arch Dermatol 1997; 133: 1172-3.
3. Sais G, Jucglà A, Peyrí J,. Prevalence of dermatophyte onychomycosis in Spain: a cross-sectional study. Br J Dermatol 1995; 132: 758-61.
4. Ghannoum MA, Hajjeh RA, Scher R, et al,. A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. J Am Acad Dermatol 2000; 43: 641-8.
5. Sigurgeirsson B, Steingrímsson O, Sveinsdõttir S,. Prevalence of onychomycosis in Iceland: a population-based study. Acta Derm Venereol 2002; 82: 467-9.
6. Gupta AK, Jain HC, Lynde CW, et al,. Prevalence and epidemiology of unsuspected onychomycosis in patients visiting dermatologists' offices in Ontario, Canada-a multicenter survey of 2001 patients. Int J Dermatol 1997; 36: 783-7.
7. Svejgaard EL, Nilsson J,. Onychomycosis in Denmark: prevalence of fungal nail infection in general practice. Mycoses 2004; 47: 131-5.
8. Gupta AK, Konnikov N, MacDonald P, et al,. Prevalence and epidemiology of toenail onychomycosis in diabetic subjects: a multicentre survey. Br J Dermatol 1998; 139: 665-71.
9. Pierard GE, Pierard-Franchimont C,. The nail under fungal siege in patients with type II diabetes mellitus. Mycoses 2005; 48: 339-42.
10. Elewski BE,. Onychomycosis. Treatment, quality of life, and economic issues. Am J Clin Dermatol 2000; 1: 19-26.
11. Drake LA, Scher RK, Smith EB, et al,. Effect of onychomycosis on quality of life. J Am Acad Dermatol 1998; 38: 702-4.
12. Turner RR, Testa MA,. Measuring the impact of onychomycosis on patient quality of life. Qual Life Res 2000; 9: 39-53.
13. Harrell TK, Necomb WW, Replogle WH, et al,. Onychomycosis: improved cure rates with itraconazole and terbinafine. J Am Board Fam Pract 2000; 13: 268-73.
14. Baran R, Sigurgeirsson B, de Berker D, et al,. A multicentre, randomized, controlled study of the efficacy, safety and cost-effectiveness of a combination therapy with amorolfine nail lacquer and oral terbinafine compared with oral terbinafine alone for the treatment of onychomycosis with matrix involvement. Br J Dermatol 2007; 157: 149-57.
15. Gupta AK, Ryder JE,. The use of oral antifungal agents to treat onychomycosis. Dermatol Clin 2003; 21: 469-79.
16. ® (voriconazole). Drug P&T Newsletter 2006; 28 November 2006.
17. Murdan S,. Drug delivery to the nail following topical application. Int J Pharm 2002; 236: 1-26.
18. Baran R, Tosti A, Hartmane I, et al,. An innovative water-soluble biopolymer improves efficacy of ciclopirox nail lacquer in the management of onychomycosis. J Eur Acad Dermatol Venereol 2009; 23: 773-81.
19. Scher RK, Tavakkol A, Sigurgeirsson B, et al,. Onychomycosis: diagnosis and definition of cure. J Am Acad Dermatol 2007; 56: 939-44.
20. Summerbell RC,. Epidemiology and ecology of onychomycosis. Dermatology 1997; 194 (Suppl. 1): 32-6.
21. Coelho LM, Aquino-Ferreira R, Maffei CM, Martinez-Rossi NM,. In vitro antifungal drug susceptibilities of dermatophytes microconidia and arthroconidia. J Antimicrob Chemother 2008; 62: 758-61.
22. Steifel Laboratories. Addendum to Original Medical Officer's Review of NDA 22-484. Center for Drug Evaluation and Research, 2010.
23. CLSI. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi; Approved Standard, 2nd edn. CLSI document M38-A2. Wayne, PA, U.S.A.: Clinical and Laboratory Standards Institute, 2008.
24. Kurtz MB, Heath IB, Marrinan J, et al,. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3,)-β- d -glucan synthase. Antimicrob Agents Chemother 1994; 38: 1480-9.
25. Kuhn DM, Chandra J, Mukherjee PK, et al,. Comparison of biofilms formed by Candida albicans and Candida parapsilosis on bioprosthetic surfaces. Infect Immun 2002; 70: 878-88.
26. Naka W, Hanyaku H, Tajima S, et al,. Application of neutral red staining for evaluation of the viability of dermatophytes and Candida in human skin scales. J Med Vet Mycol 1994; 32: 31-5.
27. Aoshim a T,. [ Observation of tinea unguium by neutral red staining ]. Nihon Ishinkin Gakkai Zasshi 2001; 42: 133-5 (in Japanese).
28. Geyer AS, Onumah N, Uyttendaele H, et al,. Modulation of linear nail growth to treat diseases of the nail. J Am Acad Dermatol 2004; 50: 229-34.
29. Del Rosso JQ,. Advances in the treatment of superficial fungal infections: focus on onychomycosis and dry tinea pedis. J Am Osteopath Assoc 1997; 97: 339-46.
30. Orentreich N, Markovsky J, Vogelman JH,. The effect of aging on the rate of linear nail growth. J Invest Dermatol 1979; 73: 126-30.
31. Hay RJ,. The future of onychomycosis therapy may involve a combination of approaches. Br J Dermatol 2001; 145 (Suppl. 60): 3-8.
32. Elewski BE,. A full 'cure' for onychomycosis is not always possible. Arch Dermatol 1999; 135: 852-3.
33. Epstein E,. How often does oral treatment of toenail onychomycosis produce a disease-free nail? An analysis of published data. Arch Dermatol 1998; 134: 1551-4.
34. Gupta AK, Lynch LE, Kogan N, et al,. The use of an intermittent terbinafine regimen for the treatment of dermatophyte toenail onychomycosis. J Eur Acad Dermatol Venereol 2009; 23: 256-62.
35. Sigurgeirsson B, Elewski BE, Rich PA, et al,. Intermittent versus continuous terbinafine in the treatment of toenail onychomycosis: a randomized, double-blind comparison. J Dermatolog Treat 2006; 17: 38-44.
36. Elewski BE, Ghannoum MA, Mayser P, et al,. Efficacy, safety and tolerability of topical terbinafine nail solution in patients with mild-to-moderate toenail onychomycosis: results from three randomized studies using double-blind vehicle-controlled and open-label active-controlled designs. J Eur Acad Dermatol Venereol 2011; (in press).
37. Gupta AK, DeDoncker P, Scher RK, et al,. Itraconazole for the treatment of onychomycosis. Int J Dermatol 1998; 37: 303-8.
38. Werschler WP, Bondar G, Armstrong D,. Assessing treatment outcomes in toenail onychomycosis clinical trials. Am J Clin Dermatol 2004; 5: 145-52.
39. DeCuyper C, Hindryckx PH,. Long-term outcomes in the treatment of toenail onychomycosis. Br J Dermatol 1999; 141 (Suppl. 56): 15-20.